Skip to main content
Fig. 7 | BMC Medical Genetics

Fig. 7

From: Silencing of microRNA-210 inhibits the progression of liver cancer and hepatitis B virus-associated liver cancer via targeting EGR3

Fig. 7

Silencing of EGR3 reversed the effect of miRNA-210 inhibitor on HepG2 and HepG2.2.15 cells. a The expression of miRNA-210 was significantly decreased by the transfection of si1- or si2-EGR3. * P < 0.05 compared with the Blank group. b Silencing of EGR3 reversed the inhibiting effect of miRNA-210 inhibitor on the viability of HepG2 and HepG2.2.15 cells. c Silencing of EGR3 reversed the promoting effect of miRNA-210 inhibitor on the apoptosis of HepG2 and HepG2.2.15 cells. * P < 0.05 compared with the miRNA + si-NC group. # P < 0.05 compared with miRNA-NC + si1-EGR3. & P < 0.05 compared with inhibitor + si1-NC. All experiments were performed in triplicate, and data were expressed as mean ± standard deviation (SD)

Back to article page

BMC Medical Genetics

ISSN: 1471-2350

Contact us